Genitourinary Cancer
From the Journals
Single-fraction radiation just misses mark for spinal compression relief
The primary noninferiority endpoint was not met, but a small difference between single- and multi-fraction radiation may not be clinically...
From the Journals
Atezolizumab/bevacizumab may offer benefit to patients with RCC
The combination performed better in renal cell carcinoma patients who were PD-L1 positive.
Conference Coverage
Combo shows promise for checkpoint inhibitor-refractory urothelial carcinoma
NATIONAL HARBOR, MD – Combination sitravatinib and nivolumab produced responses in patients with checkpoint...
From the Journals
Sunitinib for mRCC: Real-world experience differs somewhat
A cohort study finds that patients treated with sunitinib as first-line therapy in routine clinical practice had poorer overall survival but also...
From the Journals
Ezrin negativity predicts poor prognosis in clear cell RCC
Lack of this cytoskeleton linker protein was associated with adverse prognostic factors and independently predicted poorer disease-specific...
How I will treat my next patient
Is it time to expand the use of PARP inhibitors?
Dr. Alan P. Lyss breaks down new findings presented at the European Society of Medical Oncology Congress on the expanded use of PARP inhibitors in...
From the Journals
Immunotherapy enables nephrectomy with good outcomes in advanced RCC
Patients able to undergo nephrectomy after receiving immune checkpoint inhibitors had favorable surgical outcomes and pathologic responses in the...
Conference Coverage
SPARTAN: Apalutamide delays second progression in nonmetastatic CRPC
BARCELONA – The androgen receptor inhibitor also appeared to show an overall survival benefit, but it did not reach significance in an interim...
Conference Coverage
Atezolizumab plus chemo gives slight PFS edge in mUC
BARCELONA – Adding the immune checkpoint inhibitor atezolizumab to platinum-based chemotherapy offered a modest PFS benefit over chemotherapy...
From the Journals
Cancer burden: Multiple metrics needed to clarify the big picture
A cancer’s so-called epidemiologic signature – the composite pattern of incidence, mortality, and metastatic incidence – helps sort out the...
From the Journals
No difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic RCC
Therefore, the treatment should probably be directed by patient preferences, among other things, the investigators said.